T. Rowe Price Associates Portfolio holdings
T. Rowe Price Associates, Inc., founded in 1937 by Thomas Rowe Price, Jr., is a globally recognized investment management firm headquartered in Baltimore, Maryland, known for its disciplined, research-driven approach to active investing. The company manages hundreds of billions in assets, offering a wide range of mutual funds, retirement plans, and advisory services tailored to individual investors, institutions, and financial intermediaries. Emphasizing long-term growth and a conservative investment philosophy, T. Rowe Price has built a strong reputation for its equity and fixed-income funds, often focusing on fundamental analysis to identify undervalued opportunities. Still publicly traded and independent, it remains a trusted name in the industry, balancing tradition with innovation to meet evolving client needs.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Lam Research
LRCX
|
+$1.66B |
| 2 |
KLA
KLAC
|
+$1.39B |
| 3 |
T-Mobile US
TMUS
|
+$1.38B |
| 4 |
Eli Lilly
LLY
|
+$1.37B |
| 5 |
CSX Corp
CSX
|
+$1.18B |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
NVIDIA
NVDA
|
+$4.2B |
| 2 |
Microsoft
MSFT
|
+$3.24B |
| 3 |
Amazon
AMZN
|
+$2.75B |
| 4 |
Netflix
NFLX
|
+$2.53B |
| 5 |
Apple
AAPL
|
+$2.48B |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 35.66% |
| 2 | Financials | 11.78% |
| 3 | Healthcare | 11.44% |
| 4 | Consumer Discretionary | 10.75% |
| 5 | Communication Services | 10.73% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
951
Kraft Heinz
KHC
$29.1B
| $30.6M | ﹤0.01% |
1,261,222
-108,610
| -8% | -$2.7M |
|
|
LINE
952
Lineage Inc
LINE
$9.45B
| $30.3M | ﹤0.01% |
866,453
-35,150
| -4% | -$1.3M |
|
953
Snap-on
SNA
$21.1B
| $30.2M | ﹤0.01% |
87,631
+4,568
| +5% | +$1.56M |
|
|
CTRA
954
DELISTED
Coterra Energy
CTRA
| $30.2M | ﹤0.01% |
1,147,279
-3,174
| -0.3% | -$80K |
|
955
Labcorp
LH
$26.2B
| $30.1M | ﹤0.01% |
120,127
-61
| -0.1% | -$16.2K |
|
956
W.R. Berkley
WRB
$25.9B
| $30M | ﹤0.01% |
428,246
-10,572
| -2% | -$779K |
|
957
IDEX
IEX
$17.7B
| $30M | ﹤0.01% |
168,737
-205,387
| -55% | -$35.1M |
|
958
CACI
CACI
$15B
| $29.9M | ﹤0.01% |
56,168
+952
| +2% | +$538K |
|
959
Celsius Holdings
CELH
$7.28B
| $29.9M | ﹤0.01% |
653,472
+151,759
| +30% | +$7.65M |
|
960
Griffon
GFF
$4.75B
| $29.8M | ﹤0.01% |
404,493
+1,475
| +0.4% | +$110K |
|
961
ESCO Technologies
ESE
$7.78B
| $29.8M | ﹤0.01% |
152,300
+49,463
| +48% | +$10.4M |
|
962
Church & Dwight Co
CHD
$24B
| $29.6M | ﹤0.01% |
353,570
-577
| -0.2% | -$49.3K |
|
963
Expeditors International
EXPD
$24B
| $29.6M | ﹤0.01% |
198,581
-1,681
| -0.8% | -$229K |
|
964
Delek US
DK
$4.12B
| $29.5M | ﹤0.01% |
996,059
+934,448
| +1,517% | +$33.4M |
|
965
Photronics
PLAB
$1.97B
| $29.4M | ﹤0.01% |
917,420
-122,333
| -12% | -$3.16M |
|
966
Constellation Brands
STZ
$22.9B
| $29.1M | ﹤0.01% |
211,149
-1,569
| -0.7% | -$215K |
|
967
Haemonetics
HAE
$4.11B
| $28.8M | ﹤0.01% |
359,190
-3,509
| -1% | -$236K |
|
968
TETRA Technologies
TTI
$1.29B
| $28.8M | ﹤0.01% |
3,072,139
+2,948,885
| +2,393% | +$22.8M |
|
969
Inspire Medical Systems
INSP
$1.68B
| $28.4M | ﹤0.01% |
308,171
+283,243
| +1,136% | +$27.1M |
|
|
TLN
970
Talen Energy Corp
TLN
$17.5B
| $28.3M | ﹤0.01% |
75,594
-35,122
| -32% | -$13.7M |
|
971
Houlihan Lokey
HLI
$8.63B
| $28M | ﹤0.01% |
160,825
-168,623
| -51% | -$31M |
|
972
H&R Block
HRB
$6.87B
| $27.9M | ﹤0.01% |
640,918
-425,939
| -40% | -$19.9M |
|
|
MASI
973
DELISTED
Masimo
MASI
| $27.8M | ﹤0.01% |
213,594
-301,352
| -59% | -$43.2M |
|
974
T. Rowe Price US Equity Research ETF
TSPA
$4.46B
| $27.7M | ﹤0.01% |
648,407
+202,349
| +45% | +$8.61M |
|
975
Braze
BRZE
$3.12B
| $27.5M | ﹤0.01% |
802,725
+549,445
| +217% | +$16.3M |
|
Similar funds
T. Rowe Price Associates's Q4 2025 Portfolio in Review
As of Q4 2025, T. Rowe Price Associates held 3,154 positions worth $927B, down 0.78% from $935B the previous quarter. Its ten largest holdings account for 37% of the portfolio.
T. Rowe Price Associates's Q4 2025 filing shows 113 new, 1,841 increased, 860 reduced and 65 closed positions. Its largest new stake was Medline Inc: 7,325,104 shares worth $308M. The largest sale was NVIDIA, an estimated $4.2B.
By sector, the portfolio is most concentrated in Technology at 36% of assets, down from 36% a quarter earlier, followed by Financials and Healthcare.
- T. Rowe Price Associates's largest Q4 2025 buy was Medline Inc: 7,325,104 shares worth $308M.
- T. Rowe Price Associates added most to Lam Research in Q4 2025, an estimated $1.66B increase.
- T. Rowe Price Associates's biggest Q4 2025 reduction was NVIDIA, cutting an estimated $4.2B.
- T. Rowe Price Associates fully exited Akero Therapeutics in Q4 2025, selling an estimated $181M.
- T. Rowe Price Associates's ten largest holdings make up 37% of its $927B portfolio in Q4 2025.
- T. Rowe Price Associates opened 113 new positions and closed 65 in Q4 2025.
- T. Rowe Price Associates's portfolio value fell 0.78% quarter-over-quarter to $927B.
Based on T. Rowe Price Associates's 13F filing for Q4 2025, filed 17 Feb 2026.